Navigation Links
Astellas and Ambit to End Collaboration for Joint Development and Commercialization of FLT3 Kinase Inhibitors
Date:3/11/2013

TOKYO and SAN DIEGO, March 12, 2013 /PRNewswire/ -- Astellas Pharma Inc. (Astellas) (Tokyo: 4503) and Ambit Biosciences Corporation today announced the companies will end their collaboration for the joint development and commercialization of FMS-like tyrosine kinase-3 (FLT3) inhibitors, including quizartinib, effective September 3, 2013. Astellas has exercised its right to terminate the worldwide license agreement signed in 2009, and over the months ahead the companies will work together to transfer current development activities to Ambit. Upon the effective date of termination, Ambit will regain all rights granted to Astellas and continue with the quizartinib clinical trial program.

"While our decision is based on strategic reasons, we are proud of our collaborative work with Ambit, and we are committed to working with Ambit on a smooth transition," said Yoshihiko Hatanaka , President and CEO of Astellas. "We remain committed to the field of Oncology as a major area of focus for the company and will continue to pursue our goal of becoming a Global Category Leader in Oncology." 

Michael Martino , President and CEO of Ambit, said, "With the Phase 2 study results for quizartinib that were presented at the ASH Annual Meeting last December, we and members of the medical community continue to be excited about quizartinib and its potential to meet a significant, unmet need in acute myeloid leukemia (AML) patients. We are fully committed to moving forward with the Phase 3 clinical trial plan and look forward to advancing this important drug candidate toward approval."

About QuizartinibQuizartinib (AC220) is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor currently under evaluation in a Phase 2b clinical trial as monotherapy treatment for adult patients
'/>"/>

SOURCE Ambit Biosciences Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. PGA TOUR Celebrates Official Launch of the Astellas Presents Executive Womens Day Program
2. Astellas to Drive PGA TOURs New Womens Initiative
3. Astellas Highlights Progress to Advance Care of Patients with Genitourinary Cancers at ASCO-GU Annual Meeting
4. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
5. Astellas Announces Acceptance of U.S. New Drug Application for Tacrolimus Extended Release Capsules
6. Personal Connections Drive Employee Participation For Changing Tomorrow Day at Astellas
7. Astellas to Close Urogenix, North Carolina-based Urology Research Facility
8. Astellas and Fujita Health University Discover Neuronal Maturation Deficits in Patients Suffering from Schizophrenia and Bipolar Disorder
9. First sales of DIFICLIR™ by Astellas Pharma Europe triggers 10 Million Euro Milestone Payment to Optimer Pharmaceuticals
10. Ambit Biosciences Completes $50 Million Financing to Advance Lead Drug Candidate in Acute Myeloid Leukemia
11. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014  Valeant Pharmaceuticals International, Inc. ... announced it has completed the sale to Galderma of ... owned or held by Valeant for $1.4 billion in ... S.A, which recently completed its acquisition of Galderma. ... of our products to a company that is firmly ...
(Date:7/10/2014)... CVS Caremark Corporation (NYSE: CVS ) ... quarterly dividend of $0.275 (27.5 cents) per share on the ... 2014, to holders of record on July 21, 2014. ... dedicated to helping people on their path to better health ... United States . Through the company,s more than 7,600 ...
(Date:1/15/2014)... Most osteoporosis patients want a choice in the ... sponsored by Mission Pharmacal Company. The survey, conducted by ... support community, revealed that 74 percent of osteoporosis patients ... form other than a pill or a tablet. ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3
... used an electronic clinical system since its inception in 2009 ... technology with an enterprise clinical and financial solution from Prognosis ... out as a completely electronic hospital. But we realize that ... of our needs," says Jeremy Lyman, CFO at the 11-bed, ...
... IOD Incorporated™, a leading provider of integrated HIM ... announced its response to the Health and Human Services ... from October 1, 2013 to October 1, 2014. ... to HHS regulations published in 2009, the current ICD-9 ...
Cached Medicine Technology:Blue Mountain Hospital Selects Enterprise System from Prognosis HIS 2Blue Mountain Hospital Selects Enterprise System from Prognosis HIS 3IOD Incorporated Advises Healthcare Providers to Stay the Course in Preparation for ICD-10 2IOD Incorporated Advises Healthcare Providers to Stay the Course in Preparation for ICD-10 3
(Date:7/13/2014)... July 13, 2014 ECS ... commented, “As a parent of a special needs child, ... in the Seattle community for contemporary special education resources ... important alternative to students and families in the Seattle ... and environment for special education. We welcome the opportunity ...
(Date:7/13/2014)... If Dr. Lawrence Power has his way, ... at http://www.HealthYourself101.com will expand people’s understanding of the ... has set out to provide a health education platform on ... dare we say it? – entertaining to dig into and ... engage the remote learner – the solitary individual signing on ...
(Date:7/13/2014)... 13, 2014 According to the Living ... is a comprehensive guide that features a series of ... KP (keratosis pilaris). This guide consists of 14 ... Keratosis Pilaris? ,     Chapter 2: What Cause KP? ... I Have KP? ,     Chapter 4: Keratosis Pilaris ...
(Date:7/12/2014)... According to the new market research report "Security and ... Systems) - Global Forecasts and Analysis to 2014 - ... are estimated to be $6.08 billion in 2014 and ... reach $8.61 billion by 2020. , Browse more than ... 161 pages and in-depth TOC on "Security and Surveillance ...
(Date:7/12/2014)... one of the world’s leading wedding dress suppliers, has announced ... more, all these hot outfits are available at discounted prices, ... “We are proud to announce our new red evening dresses. ... In addition to the big discounts, low shipping costs also ... mean bad quality. All the red evening gowns are made ...
Breaking Medicine News(10 mins):Health News:New Private School, Emerald City School, Founded in Downtown Seattle Now Accepting 1st to 6th Grade Students Who Learn Differently 2Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 2Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 3Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 4Health News:Living With KP Book Review Exposes Jennifer Richards' Keratosis Pilaris Guide – Vkool.com 2Health News:Living With KP Book Review Exposes Jennifer Richards' Keratosis Pilaris Guide – Vkool.com 3Health News:Security and Surveillance Radar Market Estimated to Reach $8.61 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Security and Surveillance Radar Market Estimated to Reach $8.61 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Security and Surveillance Radar Market Estimated to Reach $8.61 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Discounted Red Evening Gown Announced by iFitDress.com 2
... atrophy of their temporal lobe or damage to blood ... Alzheimers disease . ,Older adults showing signs ... Alzheimers than their peers. ,Alzheimers disease, a highly ... with other risk factors such as poor cognitive scores, ...
... the University of Southern California have identified a chemical ... brain to low blood sugar levels . ... to yield new insights in the fight against diabetes, ... the researchers, the chemical travels from the hindbrain, which ...
... Australian actress Toni Collette is expecting her first child with ... the news, and said that she and her hubby are ... happy. We are completely over the moon," News.com.au quoted the ... playing pregnant women in many of her films of late, ...
... ,Pull on rubber gloves. ,Smear Vaseline over your glasses , ,and there you have ... ... - Malcolm Cowley ,Hormone ... estrogen and often progesterone for post-menopausal women. ,The two ...
... Internet for conditions ranging from cold sores and shingles ... to prevent aging, enhance fertility, prevent cancer and get ... cadmium. , ,Selenium supplements have shown some ... activities, some scientists feel it might be effective against ...
... actor would never have slept with Marilyn Monroe, for she was ... that the two had a torrid sex romp on the set ... heart attack. ,However, author David Bret in his biography ... rumour was just not true. ,Bret writes that the ...
Cached Medicine News:Health News:Neurotransmitter That can Yield New Insights in the Fight Against Diabetes Identified 2Health News:Hormone Replacement Therapy Liberation at a Cost 2Health News:Hormone Replacement Therapy Liberation at a Cost 3Health News:Selenium Supplements Could Increase Diabetes Risk 2Health News:Selenium Supplements Could Increase Diabetes Risk 3
The TransNeb is a complete medication delivery system in a bag. The TransNeb is a compact, piston compressor providing high-performance while weighing only 11 oz. Versatility. Dependability. Simplici...
... A lightweight (4.2lbs) portable unit with a unique ... It features an oil free aluminum alloy integrated ... Available in a variety of combinations with ... Carrying bag is also available. , ...
The ACMI TurboFlow 18 L and 10 L Insufflators provide rapid distention for all laparoscopic procedures. Eleven built-in safety features make insufflation reliable and dependable....
... GenoID's kit is the first ... HPV for clinical diagnostic use. , ... high-risk and 5 low-risk genotypes of ... of PCR technology but simplifying the ...
Medicine Products: